对SHP2全抑制剂 (2018年至今) 的专利审查
Alessia Petrocchi1, Alina Ciammaichella1
1Principal Research Investigator, IRBM S.p.A. - Medicinal Chemistry, Rome, Italy.
Expert opinion on therapeutic patents
|June 6, 2024
概括
在临床前的癌症模型中,SHP2 (Src同质区2含蛋白氨酸酸酶2) 抑制剂显示出有前途. 组合疗法,而不是单一疗法,是克服耐药性和证明长期益处的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- SHP2 (Src同质区2含蛋白氨酸酸酶2) 对于RAS/MAPK信号传递和PD-1/PD-L1免疫抑制至关重要.
- SHP2调节关键的细胞过程,包括增殖,生存和迁移,使其成为癌症治疗的目标.
研究的目的:
- 从2018年到现在,审查专利的SHP2全抑制剂.
- 与初始抑制剂相比,分析结构修改,SHP099.9.
主要方法:
- 在 Espacenet 和 Scifinder 数据库中搜索专利文献.
- 报告的SHP2全抑制剂的结构分析.
主要成果:
- 许多强大的SHP2全抑制剂已在临床前癌症模型中被确定并测试.
- 15种化合物正在临床试验中,但没有一个得到批准;单一疗法的疗效受到耐药性的限制.
结论:
- SHP2 抑制剂显示出临床前的有效性,但由于耐药性,在单一治疗中面临挑战.
- 针对MEK,BRAF,EGFR,RAS-G12C和PDL-1的组合疗法显示出显著的潜力,并正在进行广泛的研究.
相关概念视频
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Cooperative Allosteric Transitions
2.3K
2.3K
Allosteric Regulation
57.9K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.9K
Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K


